Parameswaran Hari

Company: Obsidian Therapeutics

Job title: Chief Development Officer

Seminars:

Improving Efficacy and Minimizing Safety Risks of TIL Cell Therapy by Rational Engineering of TIL 8:25 am

• Conventional unengineered TIL cell therapy requires the use of IL2, which is associated with T-cell exhaustion, reduced cytotoxicity, and increased immune-inhibitory regulatory T cells, thus diminishing its therapeutic potential and resulting in substantial clinical toxicity that limits the eligible patient population. • OBX-115 engineered TIL cell therapy utilizes Obsidian’s cytoDRiVE® platform to enable regulation…Read more

day: Conference Day Two